Byondis and Medac link up to commercialise trastuzumab duocarmazine

Byondis and Medac have entered into a license and collaboration agreement for form of targeted chemotherapy - News - PharmaTimes

Related Keywords

United Kingdom ,Marco Timmers ,Jacques Lemmens ,European Medicine Agency ,Regulatory Agency ,European Medicine ,Chairman Jacques ,Byondis ,Redac ,Trastuzumab Duocarmazine ,